Coagulation factor deficiency refers to a group of rare inherited or acquired disorders in which the blood lacks specific clotting factors, most notably Factor VIII (hemophilia A), Factor IX (hemophilia B), or von Willebrand factor (vWD). These deficiencies result in abnormal bleeding and pose significant health risks, requiring lifelong therapy and comprehensive care. As the burden of hemophilia and other coagulation disorders rises globally driven by genetics, diagnostics improvements, and broader disease awareness ensuring reliable supply, innovation in therapies, and robust healthcare infrastructure is critical for patients’ quality of life and long-term outcomes.
According to BIS Research, the Global Coagulation Factor Deficiency market which includes plasma-derived therapies for coagulation factor deficiency was valued in 2020 and is expected to grow steadily over the next decade, driven by increasing demand and advancements in treatment options.
Key Drivers:
Global increase in patients with blood disorders, including hemophilia A, B, and vWD
Rise in trauma patients and chronic illnesses driving demand for coagulation factors
Increased product launches and approvals of plasma-derived and recombinant therapies
Expanding research and development in plasma components, especially for neurological and rare diseases
Growing investment in plasma collection infrastructure and blood banks
Key Challenges:
Risk of transfusion-transmitted infectious diseases and adverse reactions to plasma therapies
Long duration and high cost of manufacturing process for coagulation factors
Stringent regulatory guidelines for product approvals and plasma collection
Supply chain and logistical issues for timely access, especially in low-resource regions
Explore the Full TOC and Download Report Sample
by Deficiency Type
• Hemophilia A
• Hemophilia B
• Von Willebrand Disease
• Factor XI & Factor XIII Deficiencies
• Other Deficiencies
by Product Type
• Recombinant Coagulation Factors
• Plasma-derived Coagulation Factors
• Others
by End-User
• Hospitals
• Specialty Clinics
• Others
by Region
• North America
• Europe
• Asia-Pacific
The coagulation factor deficiency market is evolving due to increased disease awareness, technological innovation, and expansion of plasma collection networks. Major players are focusing on developing safer, more effective plasma-derived and recombinant therapies to address unmet needs in both developed and emerging markets. As regulatory environments mature and diagnostics improve, patient access to life-saving treatments is likely to broaden. Key challenges remain in affordability, manufacturing complexity, and global access. However, strategic partnerships, investments in R&D, and adoption of advanced screening/testing are poised to drive market growth.
– BIS Research Analyst Team
The market is expected to grow at a CAGR of 4.90% from 2021–2031.
Key leaders include CSL Limited, Grifols S.A., Takeda Pharmaceutical Company, GC Pharma, Octapharma AG, Kedrion S.p.A, ADMA Biologics, Emergent BioSolutions, and others.
Technologies in demand include plasma-derived therapies, recombinant factor concentrates, rapid diagnostic platforms, and advanced pathogen inactivation systems.
BIS Research offers KOL-based insights, rigorous segmentation, and strategic advisory across software, hardware, and sensing tech domains.
